 |
| ConfirmMDx detects an epigenetic field effect or "halo" associated with cancer at the DNA level in cells. This halo around a cancer lesion can be present despite looking normal under a microscope.--Courtesy of MDxHealth |
Belgium's MDxHealth has partnered with generics maker Teva Pharmaceuticals ($TEVA) to commercialize its ConfirmMDx for prostate cancer and PredictMDx for glioblastoma tests in Israel.
"This partnership with Teva means that these important tests will now become available to cancer patients in Israel, our second market after the U.S.," said Dr. Jan Groen, CEO of MDxHealth, in a statement. "We are delighted that Teva has agreed to invest its significant commercialization resources into our unique cancer products, expanding access to a new and diverse patient population."
Under the terms of the agreement, Teva Pharmaceutical Industries will be the exclusive distributor of both tests in Israel for a three-year period. Teva will reimburse MDxHealth for all testing services, which will be processed at MDxHealth's laboratory in Irvine, CA. Financial terms of the deal were not disclosed.
The diagnostics company's ConfirmMDx is an epigenetic assay to help doctors rule out prostate cancer-free men from undergoing unnecessary repeat biopsies and detect high-risk patients who may require repeat biopsies and potential treatment.The PredictMDx test is used to identify glioma patients who have methylation of the MGMT gene. In clinical studies, these patients have shown the potential to respond better to certain chemotherapeutic drugs.
Last year, the company touted new studies on its ConfirmMDx test, which reaffirmed the test's usefulness in providing more personalized--and accurate--prostate cancer diagnosis when an initial biopsy comes back negative.
- here's the release